Fujian Wanchen Biotechnology Group (SZSE:300972) Could Become A Multi-Bagger

What are the early trends we should look for to identify a stock that could multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. With that in mind, the ROCE of Fujian Wanchen Biotechnology Group (SZSE:300972) looks great, so lets see what the trend can tell us.

Return On Capital Employed (ROCE): What Is It?

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on Fujian Wanchen Biotechnology Group is:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.35 = CN¥648m ÷ (CN¥6.5b - CN¥4.6b) (Based on the trailing twelve months to September 2024).

So, Fujian Wanchen Biotechnology Group has an ROCE of 35%. That's a fantastic return and not only that, it outpaces the average of 6.8% earned by companies in a similar industry.

See our latest analysis for Fujian Wanchen Biotechnology Group

In the above chart we have measured Fujian Wanchen Biotechnology Group's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Fujian Wanchen Biotechnology Group .

So How Is Fujian Wanchen Biotechnology Group's ROCE Trending?

We like the trends that we're seeing from Fujian Wanchen Biotechnology Group. The data shows that returns on capital have increased substantially over the last five years to 35%. The amount of capital employed has increased too, by 317%. So we're very much inspired by what we're seeing at Fujian Wanchen Biotechnology Group thanks to its ability to profitably reinvest capital.

On a side note, we noticed that the improvement in ROCE appears to be partly fueled by an increase in current liabilities. Effectively this means that suppliers or short-term creditors are now funding 71% of the business, which is more than it was five years ago. Given it's pretty high ratio, we'd remind investors that having current liabilities at those levels can bring about some risks in certain businesses.

In Conclusion...

A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what Fujian Wanchen Biotechnology Group has. And a remarkable 569% total return over the last three years tells us that investors are expecting more good things to come in the future. So given the stock has proven it has promising trends, it's worth researching the company further to see if these trends are likely to persist.

On a separate note, we've found 2 warning signs for Fujian Wanchen Biotechnology Group you'll probably want to know about.

High returns are a key ingredient to strong performance, so check out our free list ofstocks earning high returns on equity with solid balance sheets.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.